Resumen de acción MDNA Medicenna Therapeutics Corp., una empresa de inmunoterapia, se dedica al desarrollo y comercialización de Superkines y Superkines potenciadas para el tratamiento del cáncer y otras enfermedades. Saber más
Recompensas Análisis de riesgos + 1 riesgos adicionales
Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Medicenna Therapeutics Corp. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Medicenna Therapeutics Precios históricos de las acciones Precio actual de la acción CA$1.71 Máximo en las últimas 52 semanas CA$2.98 Mínimo de 52 semanas CA$0.39 Beta 1.11 Cambio en 1 mes 8.92% Variación en 3 meses -14.07% Cambio de 1 año 307.14% Variación en 3 años -25.65% Variación en 5 años -49.41% Variación desde la OPV -36.67%
Noticias y actualizaciones recientes
Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium Dec 14
Medicenna Therapeutics Corp Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA®? (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study Dec 05
Medicenna Therapeutics Corp. Announces Updated Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference Nov 27
Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) Nov 26
Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC Nov 12
Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Nov 08 Ver más actualizaciones
Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium Dec 14
Medicenna Therapeutics Corp Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA®? (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study Dec 05
Medicenna Therapeutics Corp. Announces Updated Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference Nov 27
Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) Nov 26
Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC Nov 12
Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Nov 08
Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference Sep 11
Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors Aug 15
Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024 Jul 22
Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe Jun 26
Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024 Jun 05
Medicenna Therapeutics Files Form 15 May 15 Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P. May 01
Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P. Apr 27
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study Apr 10
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting Mar 06
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors Feb 13
Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab Jan 09
Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp Nov 18
Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting Nov 10
Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer Nov 07
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Nov 04 Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index Nov 03
Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer
New major risk - Revenue and earnings growth Oct 28 Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY
We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully Oct 18
Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer Oct 11
Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy Oct 05
Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy Sep 29
Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer Aug 29 Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer
Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study Aug 10
Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee Aug 09
Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023 Jul 15
New minor risk - Share price stability Jun 26
Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans Jun 14
Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth Feb 28
Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023 Jan 27
Price target decreased to CA$7.00 Dec 01
High number of new and inexperienced directors Nov 16
Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting Nov 12
Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation Nov 08
Price target increased to CA$12.00 Nov 04
Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Oct 29
Lead Independent Director recently bought CA$74k worth of stock Oct 12
Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study Sep 29
Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022 Sep 24
Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial Sep 14 Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million. Aug 11
Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million. Aug 10
Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022 Aug 06
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study Jul 28
Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022 Jul 09
No longer forecast to breakeven Jun 28
Price target decreased to CA$10.63 Jun 21
Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022 Jun 09
Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022 Jun 08
Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting May 12
Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study May 04
High number of new and inexperienced directors Apr 27 Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting
Forecast to breakeven in 2025 Apr 01
Medicenna Therapeutics Corp. Announces Management Changes Mar 05
Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans? Mar 01
High number of new and inexperienced directors Feb 05
Medicenna Therapeutics Corp. to Report Q3, 2022 Results on Feb 09, 2022 Feb 03
Medicenna Therapeutics Corp. Announces Board Appointments Feb 01
Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer Jan 27
Medicenna Therapeutics Corp. Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with Mdna11 Treatment in the Phase 1/2 Ability Study Dec 23
Medicenna Therapeutics Corp. Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada Dec 18
Founder recently bought CA$106k worth of stock Nov 11
Medicenna Therapeutics Corp. Doses First Patient in MDNA11 Phase 1/2 Ability Study Sep 15
Consensus revenue estimates fall to CA$125.0k Aug 20
We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely Aug 07
Medicenna’s IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating Its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer Jul 15
Medicenna Therapeutics Corp. Announces Submission of Clinical Trial Application in Australia for A Phase 1/2 Study of Mdna11 Jun 25
Price target increased to CA$11.50 Jun 09
Price target increased to CA$11.25 Jun 02
Medicenna Therapeutics Corp. Announces Peer-Reviewed Publication of Clinical Data from Phase 2B Trial Evaluating Mdna55 in Recurrent Glioblastoma May 08
Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely? Apr 14
New 90-day low: CA$4.73 Mar 05
Price target raised to CA$11.45 Feb 19
Founder recently bought CA$52k worth of stock Jan 10
We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely Dec 30
New 90-day high: CA$6.07 Dec 24
Medicenna Therapeutics Corp. Provides Update on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme At Key Opinion Leader Call Dec 03
Medicenna Announces Upcoming Oral Presentations At the 2020 Society for Neuro-Oncology Annual Meeting Nov 19
Medicenna Therapeutics Corp. Presents Late Breaking Abstract Updating Results from Phase 2B Recurrent GBM Trial at the 36th EORTC-NCI-AACR Meeting Oct 27
Price target raised to CA$11.48 Oct 21 Rentabilidad de los accionistas MDNA CA Biotechs Mercado CA 7D -3.4% -3.6% -2.6% 1Y 307.1% 12.9% 15.2%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: MDNA superó a la industria Canadian Biotechs, que obtuvo un rendimiento del 12.9% el año pasado.
Rentabilidad vs. Mercado: MDNA superó al mercado Canadian, que obtuvo un rendimiento del 15.2% el año pasado.
Volatilidad de los precios Is MDNA's price volatile compared to industry and market? MDNA volatility MDNA Average Weekly Movement 12.8% Biotechs Industry Average Movement 13.4% Market Average Movement 8.2% 10% most volatile stocks in CA Market 17.4% 10% least volatile stocks in CA Market 2.9%
Precio estable de las acciones: El precio de las acciones de MDNA ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MDNA(13%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Canadian.
Acerca de la empresa Medicenna Therapeutics Corp., empresa de inmunoterapia, se dedica al desarrollo y comercialización de supercinas y supercinas potenciadas para el tratamiento del cáncer y otras enfermedades. Desarrolla bizaxofusp (MDNA55), un CE de interleucina 4 (IL-4) para el tratamiento del glioblastoma recurrente, así como para tumores cerebrales. La empresa también desarrolla MDNA11, una versión mejorada de la IL-2 para activar y proliferar las células inmunitarias necesarias para combatir el cáncer; MDNA209, un antagonista de la IL-2 para enfermedades autoinmunes, como la esclerosis múltiple y la enfermedad de injerto contra huésped; MDNA413, un antagonista dual IL-4/IL-13 para tratar inmunoterapias contra el cáncer; MDNA113, una superquina anti-PD1-IL2 bifuncional enmascarada para diversos tumores sólidos; y MDNA132, una superquina IL-13 para diversos tumores.
Mostrar más Resumen de fundamentos de Medicenna Therapeutics Corp. ¿Cómo se comparan los beneficios e ingresos de Medicenna Therapeutics con su capitalización de mercado? Estadísticas fundamentales de MDNA Capitalización bursátil CA$133.65m Beneficios(TTM ) -CA$26.68m Ingresos (TTM ) n/a
0.0x Ratio precio-ventas (PS)
-5.0x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de MDNA Ingresos CA$0 Coste de los ingresos CA$0 Beneficio bruto CA$0 Otros gastos CA$26.68m Beneficios -CA$26.68m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.34 Margen bruto 0.00% Margen de beneficio neto 0.00% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado MDNA a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/22 06:33 Precio de las acciones al final del día 2024/12/20 00:00 Beneficios 2024/09/30 Ingresos anuales 2024/03/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Medicenna Therapeutics Corp. está cubierta por 4 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Charles Zhu Guggenheim Securities, LLC Swayampakula Ramakanth H.C. Wainwright & Co. Catherine Novack JonesTrading Institutional Services, LLC
Mostrar 1 más analistas 
